These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase. Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813 [TBL] [Abstract][Full Text] [Related]
8. Identification of 4-[4-(4-fluoro-phenyl)-thiazol-2-ylamino]-2,6-dimethyl-phenol (KR-33749) as an inhibitor of 5-lipoxygenase with potent antiinflammatory activity. Cho YS; Kim CH; Surh JH; Kang NS; Yoo SE; Cheon HG Pharmacology; 2010; 86(2):65-72. PubMed ID: 20639685 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379 [TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. Rao NL; Dunford PJ; Xue X; Jiang X; Lundeen KA; Coles F; Riley JP; Williams KN; Grice CA; Edwards JP; Karlsson L; Fourie AM J Pharmacol Exp Ther; 2007 Jun; 321(3):1154-60. PubMed ID: 17371808 [TBL] [Abstract][Full Text] [Related]
11. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. Bell RL; Bouska JB; Malo PE; Lanni C; Harris RR; Otis ER; Stewart AO; Brooks DW; Carter GW J Pharmacol Exp Ther; 1995 Feb; 272(2):724-31. PubMed ID: 7853186 [TBL] [Abstract][Full Text] [Related]
12. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452 [TBL] [Abstract][Full Text] [Related]
13. 4-Methoxy-2-methyltetrahydropyrans: chiral leukotriene biosynthesis inhibitors, related to ICI D2138, which display enantioselectivity. Crawley GC; Briggs MT; Dowell RI; Edwards PN; Hamilton PM; Kingston JF; Oldham K; Waterson D; Whalley DP J Med Chem; 1993 Jan; 36(2):295-6. PubMed ID: 8380872 [No Abstract] [Full Text] [Related]
14. Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil. Jacobson PB; Jacobs RS J Pharmacol Exp Ther; 1992 Aug; 262(2):874-82. PubMed ID: 1323665 [TBL] [Abstract][Full Text] [Related]
15. Structure and activity relationships leading to the discovery of ICI D2138, a selective, potent and orally active inhibitor of 5-lipoxygenase. Crawley GC; Bird TG; Bruneau P; Dowell RI; Edwards PN; Foster SJ; Girodeau JM; McMillan RM; Walker ER; Waterson D J Lipid Mediat; 1993; 6(1-3):249-57. PubMed ID: 8395247 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation. Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079 [TBL] [Abstract][Full Text] [Related]
17. A-78773: a selective, potent 5-lipoxygenase inhibitor. Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248 [TBL] [Abstract][Full Text] [Related]